KAREN MCGARRY: Open Payments
NPI 1578679338 · SCHENECTADY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$375 in 13 payments from 10 companies in 2025. Trend: 2023 $409 · 2024 $450 · 2025 $375
Food & beverage: $375
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 1 | $113 |
| ABBVIE INC. | 4 | $83 |
| GlaxoSmithKline, LLC. | 1 | $26 |
| Novo Nordisk Inc | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $23 |
| SANOFI PASTEUR INC. | 1 | $22 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Abbott Laboratories | 1 | $20 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
Products named: VOQUEZNA, UBRELVY, TRELEGY ELLIPTA, Rybelsus, XIFAXAN, JARDIANCE, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, BREZTRI.
Industry payments across NY — which companies pay providers there.
